Niagen Bioscience (NASDAQ:NAGE) Posts Earnings Results, Meets Expectations

Niagen Bioscience (NASDAQ:NAGE) announced its earnings results on Wednesday. The company reported ($0.01) EPS for the quarter, hitting the consensus estimate of ($0.01), FiscalAI reports. The business had revenue of $27.19 million during the quarter. Niagen Bioscience had a net margin of 8.37% and a return on equity of 10.26%.

Niagen Bioscience Stock Down 2.1%

Shares of NASDAQ NAGE traded down $0.04 during trading hours on Friday, hitting $2.06. The company had a trading volume of 457,539 shares, compared to its average volume of 838,507. The stock has a market capitalization of $164.46 million, a P/E ratio of 17.21 and a beta of 2.12. Niagen Bioscience has a 1-year low of $2.04 and a 1-year high of $7.28. The firm’s 50 day moving average is $2.79 and its 200-day moving average is $3.85.

Wall Street Analyst Weigh In

NAGE has been the topic of several analyst reports. Roth Capital reissued a “buy” rating on shares of Niagen Bioscience in a research report on Wednesday, August 5th. Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a research note on Thursday, October 15th. Finally, Canaccord Genuity Group decreased their price objective on Niagen Bioscience from $9.00 to $7.00 and set a “buy” rating for the company in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $9.33.

Key Headlines Impacting Niagen Bioscience

Here are the key news stories impacting Niagen Bioscience this week:

• Positive Sentiment: Niagen outlined a planned 5,000-participant, three-year Mass General Brigham trial and is targeting early 2027 commercialization of NR malate, offering longer-term product and research catalysts. Article: Niagen Bioscience outlines plans for a Mass General Brigham trial
• Positive Sentiment: Third-quarter direct-to-consumer sales on the company’s website rose 13% year over year, and the earnings-call coverage highlighted positive cash flow. Article: Niagen Bioscience Q3 2026 earnings call highlights
• Neutral Sentiment: Canaccord Genuity lowered its price target from $9 to $7 but kept a Buy rating. The reduced target reflects a less bullish outlook, though it remains well above the roughly $2.08 share price cited in the report. Article: Canaccord Genuity lowers Niagen Bioscience price target
• Negative Sentiment: HC Wainwright cut its EPS forecasts across several periods, including lowering its FY2026 and FY2027 estimates from $0.14 to $0.05 per share. The revisions suggest weaker expected earnings than previously anticipated.
• Negative Sentiment: Niagen reported a third-quarter loss of $0.01 per share, matching expectations but down from $0.05 earnings a year earlier. Revenue was $27.2 million and was reported below estimates, adding pressure despite the in-line loss. Article: Niagen Bioscience reports Q3 loss and misses revenue estimates

Hedge Funds Weigh In On Niagen Bioscience

Institutional investors have recently added to or reduced their stakes in the company. SteelPeak Wealth LLC lifted its stake in Niagen Bioscience by 2.2% in the 3rd quarter. SteelPeak Wealth LLC now owns 3,577,435 shares of the company’s stock valued at $10,446,000 after purchasing an additional 77,306 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its position in Niagen Bioscience by 47.1% during the first quarter. Arrowstreet Capital Limited Partnership now owns 2,378,437 shares of the company’s stock worth $10,489,000 after buying an additional 761,685 shares during the last quarter. Tieton Capital Management LLC acquired a new position in Niagen Bioscience during the second quarter worth approximately $6,407,000. Renaissance Technologies LLC increased its position in Niagen Bioscience by 45.4% during the first quarter. Renaissance Technologies LLC now owns 1,328,843 shares of the company’s stock worth $5,860,000 after buying an additional 414,725 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Niagen Bioscience by 16.4% in the first quarter. Dimensional Fund Advisors LP now owns 1,071,133 shares of the company’s stock valued at $4,723,000 after buying an additional 150,763 shares during the period. 15.41% of the stock is currently owned by institutional investors and hedge funds.

About Niagen Bioscience

Niagen Bioscience, Inc develops and commercializes science-based products designed to support healthy aging and cellular health. The company focuses on NAD+ biology, including nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to NAD+, a coenzyme involved in cellular energy production and other biological processes.

Its principal consumer product is Tru Niagen, an NR-based dietary supplement sold through the company’s direct-to-consumer website and retail and distribution channels.